Eli Lilly’s latest weight-loss shot helped patients lose as much as 29 per cent of their body weight in trials, giving another boost to the US pharmaceutical company’s booming obesity business.
In a statement on Thursday, Lilly said that the drug, called retatrutide, also improved other measures of physical wellbeing, with one in eight patients completely free from knee pain at the end of the trial.
Participants in the late-stage trials, suffering from obesity and osteoarthritis, lost an average of 28.7 per cent of their body weight after 68 weeks, the company said, compared with a loss of 2.1 per cent for those on a placebo.
您已閱讀24%（631字），剩余76%（1991字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。